On October 9, BEONE MEDICINES fell 3.1% in regular trading, trading at HK$206.4 with turnover of HK$192 million.

The decline came as the broader innovative drug sector faced selling pressure after peer Aolis's core product failed a global Phase III trial, raising concerns over pipeline execution and weighing on sentiment across Hong Kong-listed biotech names. Despite BEONE MEDICINES' strong interim results and multiple buy ratings from institutions, recent selling by founding shareholder Wang Xiaodong in September and changes in JPMorgan's position continued to temper short-term investor confidence.

BEONE MEDICINES AG (formerly BeiGene Ltd) is a global oncology company developing novel therapies for cancer, with a portfolio spanning hematology and solid tumors, including products such as Brukinsa, Tevimbra, and Pamiparib.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)